Neha Krishnamohan - Kinnate Biopharma Principal CFO
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Insider
Neha Krishnamohan is Principal CFO of Kinnate Biopharma
| Age | 36 |
| Phone | 858 299 4699 |
| Web | https://www.kinnate.com |
Neha Krishnamohan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Neha Krishnamohan against Kinnate Biopharma stock is an integral part of due diligence when investing in Kinnate Biopharma. Neha Krishnamohan insider activity provides valuable insight into whether Kinnate Biopharma is net buyers or sellers over its current business cycle. Note, Kinnate Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kinnate Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Neha Krishnamohan over a year ago Payment of 1721 shares by Neha Krishnamohan of Kinnate BiopharmaInc subject to Rule 16b-3 | ||
Neha Krishnamohan over a year ago Acquisition by Neha Krishnamohan of 215000 shares of Kinnate BiopharmaInc subject to Rule 16b-3 |
Kinnate Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.3363) % which means that it has lost $0.3363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.558) %, meaning that it created substantial loss on money invested by shareholders. Kinnate Biopharma's management efficiency ratios could be used to measure how well Kinnate Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Kinnate Biopharma currently holds 3.17 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Kinnate Biopharma has a current ratio of 22.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Kinnate Biopharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| FACC MD | Stoke Therapeutics | 61 | |
| Mark Wallet | Century Therapeutics | N/A | |
| Christopher Garcia | Surrozen | N/A | |
| Lauren White | C4 Therapeutics | N/A | |
| Tracy Rarick | Windtree Therapeutics | N/A | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| John CPA | Windtree Therapeutics | 60 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Christopher MSc | Keros Therapeutics | 50 | |
| MBA MD | Generation Bio Co | 55 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Joo MD | Design Therapeutics | 61 | |
| Calvin MD | Surrozen | N/A | |
| MBA MD | Surrozen | 56 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| Wei MD | Erasca Inc | 54 | |
| Roeland Nusse | Surrozen | 74 | |
| Nancy Ruiz | Larimar Therapeutics | N/A | |
| Michael Diem | Century Therapeutics | 53 | |
| Elizabeth Nguyen | Surrozen | N/A | |
Management Performance
| Return On Equity | -0.56 | |||
| Return On Asset | -0.34 |
Kinnate Biopharma Leadership Team
Elected by the shareholders, the Kinnate Biopharma's board of directors comprises two types of representatives: Kinnate Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kinnate. The board's role is to monitor Kinnate Biopharma's management team and ensure that shareholders' interests are well served. Kinnate Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kinnate Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kania, Senior Research | ||
| Richard MBBS, Chief Officer | ||
| Jason MD, VP Quality | ||
| Neha Krishnamohan, Principal CFO | ||
| Barbara Warren, VP Culture | ||
| Mark Meltz, General COO | ||
| Nima MBA, CEO President | ||
| Priyanka Shah, VP Communications |
Kinnate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kinnate Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (25.71 M) | |||
| Shares Outstanding | 47.17 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 82.58 % | |||
| Number Of Shares Shorted | 465.63 K | |||
| Price To Book | 0.79 X | |||
| EBITDA | (118.21 M) | |||
| Net Income | (112.65 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |